A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in Combination With Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects With Hepatocellular Carcinoma

NCT06695026 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma (HCC)

Interventions

DRUG: RZ-001 Dose 1
DRUG: RZ-001 Dose 2
DRUG: RZ-001 Dose 3

Sponsor

Rznomics, Inc.